FDA Grants Fast Track Designation to IMM-1-104 in NRAS+ Advanced Melanoma
The FDA has granted fast track designation to IMM-1-104 for the treatment of advanced melanoma.
Related Articles
The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023
Experts Highlight Advances and Future Directions for Adjuvant Ribociclib in HR+/HER2– Breast Cancer
Experts at the 2024 San Antonio Breast Cancer Symposium discussed knowledge gaps in understanding how best to use ribociclib in treating patients with early breast…
Home – Cell Symposia: The cancer immunity cycle
Cell Symposia: Infection Biology in the Age of the Microbiome
Lancet Breast Cancer Commission Report Addresses Challenges to Reduce Disease Burden
Reshma Jagsi, MD, DPhil, highlights key takeaways from the Lancet Breast Cancer Commission Report and the necessary steps forward emphasized in the report.
Certain Breast Cancer Subtypes May Derive a Greater Benefit With Ribociclib Combo vs Chemo
Patients with luminal B and HER2E breast cancer subtypes may have a greater PFS benefit with ribociclib plus endocrine therapy vs combination chemotherapy.
Optimizing Treatment Sequences Remains Key in CLL/SLL
Real-world data presented at the 2024 ASH Annual Meeting evaluated the efficacy of the most common treatment sequences in CLL/SLL.
Tafasitamab Plus Lenalidomide/Rituximab Improves PFS in Relapsed/Refractory Follicular Lymphoma
Tafasitamab plus lenalidomide and rituximab improved median PFS vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
China’s NMPA Grants Breakthrough Therapy Designation to Savolitinib Plus Osimertinib in EGFR+ NSCLC
Savolitinib plus osimertinib received breakthrough therapy designation in China for pretreated, locally advanced or metastatic EGFR-positive NSCLC with MET amplification.
Selinexor Plus Ruxolitinib Displays Activity in Ruxolitinib-Pretreated Myelofibrosis
Selinexor plus ruxolitinib showed activity in patients with myelofibrosis who were treated with ruxolitinib.
Unpacking Key Data From the 2024 ASH Annual Meeting: With Andre Goy, MD
Andre Goy, MD, discusses top hematologic oncology research from the 2024 ASH Annual Meeting.